Search

Search Constraints

You searched for: Author/Creator Luthman, Johan

Search Results

1. 2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception. Issue 6 (1st June 2015)

2. [O2–09–03]: PHASE 1 INVESTIGATION INTO THE SAFETY, TOLERABILITY, PHARMACOKINETICS (PK) AND PHARMACODYNAMICS (PD) OF E2027, A SELECTIVE PHOSPHODIESTERASE‐9 (PDE9) INHIBITOR. (1st July 2017)

3. [P1–056]: POPULATION PHARMACOKINETIC‐PHARMACODYNAMIC (PK/PD) MODELING OF E2027, A SELECTIVE PHOSPHODIESTERASE‐9 (PDE9) INHIBITOR, FOLLOWING SINGLE ASCENDING ORAL DOSES IN HEALTHY VOLUNTEERS. (1st July 2017)

4. A multinational study distinguishing Alzheimer's and healthy patients using cerebrospinal fluid tau/Aβ42 cutoff with concordance to amyloid positron emission tomography imaging. Issue 1 (6th March 2017)

5. ADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trials. Issue 9 (23rd March 2016)

6. Blood‐based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic. Issue 1 (18th November 2016)

7. Building a roadmap for developing combination therapies for Alzheimer's disease. (March 2014)

8. Charting a path toward combination therapy for Alzheimer's disease. (January 2014)

10. DT‐01‐07: TREATMENT OF EARLY AD SUBJECTS WITH BAN2401, AN ANTI‐Aβ PROTOFIBRIL MONOCLONAL ANTIBODY, SIGNIFICANTLY CLEARS AMYLOID PLAQUE AND REDUCES CLINICAL DECLINE. (1st July 2006)